From the Editor in Chief: Science, Control, and the Seemingly Uncontrollable - - BioPharm International

ADVERTISEMENT

From the Editor in Chief: Science, Control, and the Seemingly Uncontrollable


BioPharm International
Volume 19, Issue 8

What do you do about something that seems incredibly useful, but is inherently uncontrollable? This is the challenge posed by phage therapy.


Laura Bush
Phage therapy appears to be an elegant solution to the problem of bacterial resistance to antibiotics. Phage therapy is not new; it has been practiced since the early 1900s, most notably Russia. The principle is fascinating: it uses bacteriophages, tiny viruses that live by infecting and destroying specific bacteria. Phage therapy avoids the resistance problem because the phages evolve as the bacteria evolve. Biology adapts to biology; both organisms evolve and flow in relation to each other.

The challenge lies in ensuring the safety of such therapy, and even proving its efficacy using traditional approaches to clinical trial design. In hopes of getting FDA approval, some companies are working on ways to modify phages so that they can characterize and control the phages better, but these approaches run the risk of eliminating the very feature that was desired: the ability of the living organism to adapt and remain effective against mutating bacteria that cause infection and death.

In today's biopharmaceutical industry, regulatory authorities and companies alike strive to apply good science to every action, particularly in manufacturing controls. The days when we ran a manufacturing step for X minutes because "it seems to produce good quality" are on their way out. Today's approach applies manufacturing science to achieve in-depth process understanding; process developers identify the critical quality attributes required in the end product and the critical process parameters that will ensure that those quality attributes are achieved consistently. As a result, a quiet revolution in process validation is taking place. Instead of believing that three successful batches in a row means a process is validated, companies are using design of experiments up front to develop robust process understanding and a defined design space, so that they have knowledge, backed by hard data, about the allowable limits of process variability.

FDA has been at the forefront of this drive to apply sound science, starting in 2002 with its CGMP and PAT initiatives. Now FDA is on to the next stage, implementing new harmonized approaches, rooting out old guidances that reflect outdated thinking, and working to revise the guidance on process validation to reflect a scientific approach. The agency is restructuring offices and systems involved in reviewing applications for new product approvals. In short, FDA is hammering away to ensure that this thinking pervades every level of the organization and every aspect of what they do, from each review of an investigational new drug application to every site inspection.

Can this emphasis on careful control be reconciled with phage therapy, the very effectiveness of which lies in its variability?

I can't envision a way to ensure the safety and efficacy of phage therapy that follows the rigorous scientific approaches that FDA and industry apply to protect patients. Is there a creative solution? I hope so. In the meantime, some companies are starting by finding applications in agriculture. Perhaps those will lead us to a way to resolve this fascinating conundrum.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here